Presentation on theme: "Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical."— Presentation transcript:
Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG-0403) Y. Nagata *, M. Hiraoka #, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru, E. Kunieda, S. Ishikura Radiation Therapy Study Group of Japan Clinical Oncology Group *Study Coordinator, # Primary Investigator ASTRO, Boston, Oct. 28-31, 2012.
Stereotactic body radiation therapy (SBRT) delivers very targeted beams of radiation to a small area over a few days SBRT is less invasive than surgery SBRT is considered to work against T1N0M0 lung cancers First report for operable population was presented in ASTRO 2010. This presentation is the first report for inoperable population.
First clinical trial to study SBRT for both inoperable & operable stage IA lung cancers From 2004 to 2008, 104 patients from 15 institutions with early-stage inoperable non- small cell lung cancer were studied Patients underwent 4 times daily radiotherapy over the course of four to eight days Each treatment is non-invasive and painless, much like receiving an X-ray
Patients followed for almost three years (37 months) after treatment Overall survival rate for patients three years after SBRT was 60 percent Patients reported only mild side effects from the treatment Patients with inoperable early lung cancer should consider this treatment
Conv RT vs. SBRT AuthorNumberAgeStage Dose (med) / Daily dose 3-y OS 5-y OSYear Morita14950-89I 55-75 (64.7)/ 2Gy 34.2 22.21980-1989 Sibley14146-95I 50-80 (64)/ 1.8- 3.0Gy:QD 1.2- 1.6Gy:BID 39(2-y) 131980-1995 Krol10856-88I 60-65/ 2.5-3Gy 31 151978-1992 This study 104 78 (59- 90) IA48/12Gy 59.9* 40.8*2004-2008 * In all eligible patients (n=100)